The ubiquitin proteasome system (UPS) degrades individual proteins in a highly regulated
fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular …

Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system,
has emerged as an attractive novel cancer chemotherapeutic modality. Although …

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

Adaptive resistance of myeloma to proteasome inhibition represents a clinical challenge,
whose biology is poorly understood. Proteasome mutations were implicated as underlying …

Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic
target. Today, proteasome inhibitors are a mainstay in the treatment of multiple myeloma …

Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such
as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma …

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying
anti-rheumatic drugs or biological agents are not always effective, hence driving the demand …

Previously, we demonstrated that linear peptide epoxyketones targeting the
immunoproteasome (iP) could ameliorate cognitive deficits in mouse models of Alzheimer's …